查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370880

多重癌症篩檢市場 - 2018-2028 年全球產業規模、佔有率、趨勢、競爭、機會和預測，按測試類型、技術、樣本、方法、癌症類型、按應用、最終用戶、地區和競賽

Multicancer Screening Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Test Type, By Technology, By Sample, By Method, By Cancer Type, By Application, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

多種癌症篩檢市場正在全球範圍內獲得巨大的關注。多種癌症篩檢有可能從單一血液樣本中發現多種癌症。目前世界上可進行的多種癌症篩檢測試包括血液檢查、影像學測試、基因測試、液體活體組織切片、糞便測試等。在各種類型的測試中，液體活體組織切片測試最為突出，因為它可以快速進行，提供基因組、蛋白質組和代謝組資訊，並且比組織活體組織切片的侵入性更小。乳癌、肺癌、大腸癌、胰臟癌、肝癌、卵巢癌、胃癌、食道癌和攝護腺癌是一些可以透過多種癌症篩檢測試輕鬆檢測到的癌症類型。世界各國尤其是澳洲、紐西蘭、愛爾蘭、匈牙利和美國的癌症盛行率不斷上升，增加了預測期內對多種癌症篩檢測試的需求。政府為提高各國醫療服務品質而提供的支援的成長也正在推動預測期內的全球多癌症篩檢市場。此外，政府每年都積極參與採取預防措施，透過實施新的衛生政策和引入醫療保險來控制癌症在各國的盛行率。此外，該國老年人口的成長以及與人類相關的某些類型癌症的盛行率增加，尤其是在老年時期，預計也將在未來幾年推動全球多癌症篩檢市場的發展。

慢性病盛行率增加

癌症是全球主要死亡原因之一，由於人口老化、生活方式的改變和環境因素等多種因素，預計未來幾年癌症的發生率將持續上升。發展中國家地區最常見的癌症類型是乳癌。例如，在美國，2023 年約有 3,00,590 例乳癌新病例被診斷為乳癌。繼乳癌之後世界上正在出現的另一種癌症包括肺癌、大腸癌、攝護腺癌、胃腸癌、肝癌和子宮頸癌。根據世界衛生組織（WHO）2022年發布的報告，2020年全球約有226萬例乳癌病例，其次是肺癌221萬例、結腸癌和直腸癌193萬例、癌症141萬例。前列腺癌、120萬例皮膚癌（非黑色素瘤）和109 萬例胃癌。全球癌症盛行率不斷上升，導致各國死亡率逐年顯著上升。根據世界癌症研究基金會發布的全球癌症發生率報告，丹麥的癌症發生率最高，為每10萬人口326.1例，其次是愛爾蘭，每10萬人中有317例，澳洲有314.1例，紐西蘭是每10萬人中癌症發生率最高的國家。每 10 萬人口中有 309.2 例，比利時有 306.8 例，依此類推。多種癌症的盛行率不斷上升，增加了世界對多癌篩檢設備的需求，這種設備可以提前檢測多種癌症的症狀，從而降低世界死亡率，預計這將進一步推動全球多癌症篩檢市場的發展。預測期。

市場概況
預測期 2024-2028
2022 年市場規模 90106萬美元
2028 年市場規模 190143萬美元
2023-2028 年年複合成長率 13.22%
成長最快的細分市場 醫院
最大的市場 北美洲

政府支持的增加

多癌篩檢市場是指開發和銷售可以檢測個人各種癌症類型的測試和服務。政府的支持可以在推動該市場的成長方面發揮重要作用。許多政府正在投資癌症篩檢測試和技術的研發。例如，美國國家癌症研究所為各種多癌症篩檢試驗和研究提供資金。它們在製定激勵或強制癌症篩檢的政策方面也發揮著至關重要的作用。

老年人口增加

隨著年齡的成長，人們患癌症的風險增加，這刺激了該國老年人口對癌症篩檢測試的需求。通常在全國老年人中診斷出的一些最常見的癌症類型包括胰腺癌、皮膚癌、膀胱癌、淋巴瘤、白血病、前列腺癌等。根據國際癌症控制聯盟（UICC）2023年發布的報告，70歲以上老年人中約有720萬人被診斷出罹患癌症，其中約440萬人因癌症死亡。然而，近年來老年人預防癌症的意識不斷增強，預計在預測期內全球多癌篩檢市場將實現利潤豐厚的成長。

市場區隔

全球多癌篩檢市場根據測試類型、技術、樣本、方法、癌症類型、應用、最終用戶和地區進行細分。就測試類型而言，多重癌症篩檢市場分為實驗室開發測試（LDT）和體外診斷（IVD）。從技術角度來看，全球多癌篩檢市場分為新一代定序（NGS）、聚合酶鍊式反應（PCR）、免疫組織化學（IHC）、螢光原位雜合技術（FISH）等技術。根據樣本，多癌篩檢市場分為組織、血液、唾液和口腔拭子等。基於這種方法，市場被細分為 DNA、RNA 和蛋白質。根據癌症類型，全球多癌篩檢市場分為乳癌和婦科、胃腸道、內分泌、泌尿生殖、皮膚、腦部/神經系統、肉瘤、血液惡性腫瘤、肺癌、頭頸癌和其他癌症類型。根據應用，市場分為臨床和研究。根據最終用戶，市場分為醫院、診斷和臨床實驗室、學術研究機構和其他最終用戶。

市場參與者

Agilent Technologies, Inc., Atara Biotherapeutics, Inc., Burning Rock Biotech Limited, Exact Sciences Corp., F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., 臻及生技有限公司, Guardant Health, Inc. 、 Illumina, Inc. (GRAIL, LLC.) 和Konica Minolta, Inc. (Ambry Genetics)。

報告範圍：

在本報告中，除了以下詳細介紹的產業趨勢外，全球多癌症篩檢市場也分為以下幾類。

多種癌症篩檢市場，依測試類型：

  • 實驗室開發的測試 (LDT)
  • 體外診斷 (IVD)

多重癌症篩檢市場（按技術）：

  • 新一代定序 (NGS)
  • 聚合酶鍊式反應 (PCR)
  • 免疫組織化學 (IHC)
  • 螢光原位雜合技術 (FISH)
  • 其他技術

多種癌症篩檢市場（按樣本）：

  • 組織
  • 血
  • 唾液和頰拭子
  • 其他

多種癌症篩檢市場，依方法：

  • 脫氧核糖核酸
  • 核糖核酸
  • 蛋白質

多種癌症篩檢市場，依癌症類型分類：

  • 乳房及婦科
  • 胃腸道
  • 內分泌
  • 泌尿生殖系統
  • 皮膚
  • 大腦/神經系統
  • 肉瘤
  • 血液系統惡性腫瘤
  • 肺
  • 頭部和頸部
  • 其他癌症類型

多癌篩檢市場，按應用：

  • 臨床
  • 研究

多種癌症篩檢市場，依最終用戶分類：

  • 醫院
  • 診斷和臨床實驗室
  • 學術研究機構
  • 其他最終用戶

全球多癌篩檢市場（按地區）：

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 亞太
  • 中國
  • 印度
  • 韓國
  • 澳洲
  • 日本
  • 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 南美洲
  • 巴西
  • 阿根廷
  • 哥倫比亞
  • 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

競爭格局

  • 公司簡介：全球多癌篩檢市場主要公司的詳細分析。

可用的客製化：

  • 根據給定的市場資料，TechSci Research 可根據公司的具體需求提供客製化服務。該報告可以使用以下自訂選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球多癌症篩檢市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 依測試類型（實驗室開發測試 (LDT)、體外診斷 (IVD)）
    • 依技術（次世代定序 (NGS)、聚合酶鏈反應 (PCR)、免疫組織化學 (IHC)、螢光原位雜合技術 (FISH) 和其他技術）
    • 依樣本（組織、血液、唾液和口腔拭子等）
    • 依方法（DNA、RNA 和蛋白質）
    • 依癌症類型（乳癌和婦科、胃腸道、內分泌、泌尿生殖、皮膚、腦/神經系統、肉瘤、血液惡性腫瘤、肺癌、頭頸癌和其他癌症類型）
    • 按應用（臨床、研究）
    • 按最終用戶（醫院、診斷和臨床實驗室、學術研究機構和其他最終用戶）
    • 按地區
    • 按公司分類 (2022)
  • 產品市場地圖

第 6 章：北美多癌症篩檢市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 按測試類型
    • 依技術
    • 按樣品
    • 依方法
    • 按癌症類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲多癌症篩檢市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 按測試類型
    • 依技術
    • 按樣品
    • 依方法
    • 按癌症類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區多種癌症篩檢市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 按測試類型
    • 依技術
    • 按樣品
    • 依方法
    • 按癌症類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲多癌篩檢市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 按測試類型
    • 依技術
    • 按樣品
    • 依方法
    • 按癌症類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲多癌症篩檢市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 按測試類型
    • 依技術
    • 按樣品
    • 依方法
    • 按癌症類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非多種癌症篩檢
    • 沙烏地阿拉伯多種癌症篩檢
    • 阿拉伯聯合大公國多種癌症篩檢

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

第 13 章：大環境分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（上市公司）
  • 最近的發展
  • SWOT分析
    • Agilent Technologies, Inc.
    • Atara Biotherapeutics, Inc.
    • Burning Rock Biotech Limited
    • Exact Sciences Corp.
    • F. Hoffmann-La Roche Ltd.
    • Fulgent Genetics, Inc.
    • Genecast Biotechnology Co., Ltd.
    • Guardant Health, Inc.
    • Illumina, Inc. (GRAIL, LLC.)
    • Konica Minolta, Inc. (Ambry Genetics.)

第 16 章：策略建議

第 17 章：關於我們與免責聲明

簡介目錄
Product Code: 15592

Multi-cancer screening market is gaining significant traction across the world. Multi-cancer screening has the potential to find more than one type of cancer from a single sample of blood. Several types of multicancer screening tests that are currently accessible in the world include blood tests, imaging tests, genetic tests, liquid biopsy, stool tests, and others. Among various types of tests, the liquid biopsy test is the most prominent since it can be carried out rapidly, provides genomic, proteomic, and metabolomic information, and is less invasive than tissue biopsies. Breast cancer, lung cancer, colorectal cancer, pancreatic cancer, liver cancer, ovarian cancer, stomach cancer, esophageal cancer, and prostate cancer are some of the cancer types that can be easily detected through multi-cancer screening tests. The increasing prevalence of cancer in various countries of the world especially Australia, New Zealand, Ireland, Hungary, and the United States of America is increasing the demand for multicancer screening tests during the forecast period. Growth in the support provided by the government to improve the quality of medical services provided in every country is also propelling the global multicancer screening market in the forecast period. Moreover, the government is actively participating in taking preventive measures, for controlling the prevalence of cancer in every country by the implementation of new health policies and introduction of healthcare insurance every year. Furthermore, the growth in the geriatric population of the country and the increase in the prevalence of certain types of cancers, which are associated with people, especially during their elder age is also expected to boost the global multicancer screening market in upcoming years.

Increasing Prevalence of Chronic Diseases

Cancer is one of the leading causes of death worldwide, and the incidence of cancer is expected to continue to rise in the coming years due to various factors such as aging populations, changes in lifestyle, and environmental factors. The most common type of cancer prevailing in the regions of developing countries is breast cancer. For instance, in the United States of America, around 3,00,590 new cases of breast cancer were diagnosed of breast cancer in 2023. Another type of cancers, which is emerging in the world followed by breast cancer comprises of lung cancer, colorectal cancer, prostate cancer, stomach cancer, liver cancer, and cervical cancer. According to the report published by the World Health Organization (WHO) in 2022, around 2.26 million cases of breast cancer were worldwide in 2020, followed by 2.21 million cases of lung cancer, 1.93 million cases of colon and rectum cancer, 1.41 million cases of prostate cancer, 1.20 million cases of skin cancer (non-melanoma) and 1.09 million cases of stomach cancer. The growing prevalence of cancer in the world is resulting in a noticeable rise in the mortality rate of each country with every passing year. As per the report published by World Cancer Research Fund on global cancer rates, it has been concluded that Denmark has recorded the highest cancer rate of 326.1 cases per 1,00,000 population, followed by Ireland with 317 cases, Australia with 314.1 cases, New Zealand with 309.2 cases and Belgium with 306.8 per 1,00,000 population and so on. The growing prevalence of several kinds of cancers is increasing the demand for multicancer screening devices in the world which can detect symptoms of multiple cancer beforehand and can thereby decrease the mortality rate of the world, which is further expected to propel the global multicancer screening market during the forecast period.

Market Overview
Forecast Period2024-2028
Market Size 2022USD901.06 Million
Market Size 2028USD1901.43 Million
CAGR 2023-202813.22%
Fastest Growing SegmentHospitals
Largest MarketNorth America

Growth in Government Support

The Multicancer screening market refers to the development and sale of tests and services that can detect various types of cancers in individuals. Government support can play a significant role in driving growth in this market. Many governments are investing in research and development of cancer screening tests and technologies. For instance, the National Cancer Institute in the United States provides funding for various multicancer screening trials and studies. They also play a crucial role in shaping policies that incentivize or mandate cancer screening.

Moreover, governing bodies of every country also launch public awareness campaigns to promote cancer screening and early detection. These campaigns focus on educating people about the importance of regular screening for cancer and encourage them to get screened.

Furthermore, governments can collaborate with private companies and organizations to advance cancer screening technologies. In the case of cancer screening programs, Public-private partnerships (PPPs) may be formed to increase awareness and access to screening, reduce costs, and improve the quality of screening services. Development in the support provided by the government to reduce the prevalence of cancer in every country along with the introduction of new health insurance plans every year is expected to register impressive growth in the global multicancer screening market in upcoming years.

Increase in Geriatric Population

With growing age, the risk of developing cancer increases in people, which is fueling the demand for cancer screening tests among the elderly population in the country. Some of the most common types of cancers, which are usually diagnosed in elderly people across the country include pancreatic cancer, skin cancer, bladder cancer, lymphoma, leukemia, prostate cancer, and others. According to the report published by Union for International Cancer Control (UICC) in 2023, it has been observed that around 7.2 million of those above 70 years of age were diagnosed with cancer and approximately 4.4 million of them resulted in death due to cancer. However, growing awareness among geriatric people in passing years to prevent themselves from cancer is expected to register a lucrative growth in the global multicancer screening market during the forecast period.

Market Segmentation

The global multicancer screening market is segmented based on test type, technology, sample, method, cancer type, application, end user, and region. In terms of test type, the multicancer screening market is categorized into laboratory-developed tests (LDTs) and in-vitro diagnostics (IVDs). Based on technology, the global multicancer screening market is fragmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), Immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH), and other technologies. Based on sample, the multicancer screening market is categorized into tissue, blood, saliva and buccal swab, and others. Based on this method, the market is segmented into DNA, RNA, and proteins. Based on cancer type, the global multicancer screening market is fragmented into breast and gynecologic, gastrointestinal, endocrine, genitourinary, skin, brain/nervous system, sarcoma, hematological malignancies, lung, head and neck, and other cancer types. Based on application, the market is segmented into clinical and research. Based on end user, the market is segmented into hospitals, diagnostic and clinical laboratories, academic research institutions, and other end users.

Market Players

Agilent Technologies, Inc., Atara Biotherapeutics, Inc., Burning Rock Biotech Limited, Exact Sciences Corp., F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., Genecast Biotechnology Co., Ltd., Guardant Health, Inc., Illumina, Inc. (GRAIL, LLC.), and Konica Minolta, Inc. (Ambry Genetics).

Report Scope:

In this report, the global multicancer screening market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Multicancer Screening Market, By Test Type:

  • Laboratory Developed Tests (LDTs)
  • In-Vitro Diagnostics (IVDs)

Multicancer Screening Market, By Technology:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Fluorescence In-Situ Hybridization (FISH)
  • Other Technologies

Multicancer Screening Market, By Sample:

  • Tissue
  • Blood
  • Saliva and Buccal Swab
  • Others

Multicancer Screening Market, By Method:

  • DNA
  • RNA
  • Proteins

Multicancer Screening Market, By Cancer Type:

  • Breast and Gynecologic
  • Gastrointestinal
  • Endocrine
  • Genitourinary
  • Skin
  • Brain/Nervous System
  • Sarcoma
  • Hematological Malignancies
  • Lung
  • Head and Neck
  • Other Cancer Types

Multicancer Screening Market, By Application:

  • Clinical
  • Research

Multicancer Screening Market, By End User:

  • Hospitals
  • Diagnostic and Clinical Laboratories
  • Academic Research Institutions
  • Other End Users

Global Multicancer Screening Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the global multicancer screening market.

Available Customizations:

  • With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Multicancer Screening Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value & Volume
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Laboratory Developed Tests (LDTs), In-Vitro Diagnostics (IVDs))
    • 5.2.2. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), and Other Technologies)
    • 5.2.3. By Sample (Tissue, Blood, Saliva and Buccal Swab, and Others)
    • 5.2.4. By Method (DNA, RNA, and Proteins)
    • 5.2.5. By Cancer Type (Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, and Other Cancer Types)
    • 5.2.6. By Application (Clinical, Research)
    • 5.2.7. By End User (Hospitals, Diagnostic and Clinical Laboratories, Academic Research Institutions, and Other End Users)
    • 5.2.8. By Region
    • 5.2.9. By Company (2022)
  • 5.3. Product Market Map

6. North America Multicancer Screening Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Technology
    • 6.2.3. By Sample
    • 6.2.4. By Method
    • 6.2.5. By Cancer Type
    • 6.2.6. By Application
    • 6.2.7. By End User
    • 6.2.8. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Multicancer Screening Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value & Volume
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Sample
        • 6.3.1.2.4. By Method
        • 6.3.1.2.5. By Cancer Type
        • 6.3.1.2.6. By Application
        • 6.3.1.2.7. By End User
    • 6.3.2. Mexico Multicancer Screening Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value & Volume
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Sample
        • 6.3.2.2.4. By Method
        • 6.3.2.2.5. By Cancer Type
        • 6.3.2.2.6. By Application
        • 6.3.2.2.7. By End User
    • 6.3.3. Canada Multicancer Screening Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value & Volume
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Sample
        • 6.3.3.2.4. By Method
        • 6.3.3.2.5. By Cancer Type
        • 6.3.3.2.6. By Application
        • 6.3.3.2.7. By End User

7. Europe Multicancer Screening Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Technology
    • 7.2.3. By Sample
    • 7.2.4. By Method
    • 7.2.5. By Cancer Type
    • 7.2.6. By Application
    • 7.2.7. By End User
    • 7.2.8. By Country
  • 7.3 Europe: Country Analysis
    • 7.3.1. France Multicancer Screening Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value & Volume
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Sample
        • 7.3.1.2.4. By Method
        • 7.3.1.2.5. By Cancer Type
        • 7.3.1.2.6. By Application
        • 7.3.1.2.7. By End User
    • 7.3.2. Germany Multicancer Screening Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value & Volume
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Sample
        • 7.3.2.2.4. By Method
        • 7.3.2.2.5. By Cancer Type
        • 7.3.2.2.6. By Application
        • 7.3.2.2.7. By End User
    • 7.3.3. United Kingdom Multicancer Screening Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value & Volume
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Sample
        • 7.3.3.2.4. By Method
        • 7.3.3.2.5. By Cancer Type
        • 7.3.3.2.6. By Application
        • 7.3.3.2.7. By End User
    • 7.3.4. Italy Multicancer Screening Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value & Volume
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Sample
        • 7.3.4.2.4. By Method
        • 7.3.4.2.5. By Cancer Type
        • 7.3.4.2.6. By Application
        • 7.3.4.2.7. By End User
    • 7.3.5. Spain Multicancer Screening Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value & Volume
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Sample
        • 7.3.5.2.4. By Method
        • 7.3.5.2.5. By Cancer Type
        • 7.3.5.2.6. By Application
        • 7.3.5.2.7. By End User

8. Asia-Pacific Multicancer Screening Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Technology
    • 8.2.3. By Sample
    • 8.2.4. By Method
    • 8.2.5. By Cancer Type
    • 8.2.6. By Application
    • 8.2.7. By End User
    • 8.2.8. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Multicancer Screening Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value & Volume
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Sample
        • 8.3.1.2.4. By Method
        • 8.3.1.2.5. By Cancer Type
        • 8.3.1.2.6. By Application
        • 8.3.1.2.7. By End User
    • 8.3.2. India Multicancer Screening Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value & Volume
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Sample
        • 8.3.2.2.4. By Method
        • 8.3.2.2.5. By Cancer Type
        • 8.3.2.2.6. By Application
        • 8.3.2.2.7. By End User
    • 8.3.3. South Korea Multicancer Screening Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value & Volume
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Sample
        • 8.3.3.2.4. By Method
        • 8.3.3.2.5. By Cancer Type
        • 8.3.3.2.6. By Application
        • 8.3.3.2.7. By End User
    • 8.3.4. Japan Multicancer Screening Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value & Volume
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Sample
        • 8.3.4.2.4. By Method
        • 8.3.4.2.5. By Cancer Type
        • 8.3.4.2.6. By Application
        • 8.3.4.2.7. By End User
    • 8.3.5. Australia Multicancer Screening Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value & Volume
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Sample
        • 8.3.5.2.4. By Method
        • 8.3.5.2.5. By Cancer Type
        • 8.3.5.2.6. By Application
        • 8.3.5.2.7. By End User

9. South America Multicancer Screening Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Technology
    • 9.2.3. By Sample
    • 9.2.4. By Method
    • 9.2.5. By Cancer Type
    • 9.2.6. By Application
    • 9.2.7. By End User
    • 9.2.8. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Multicancer Screening Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value & Volume
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Sample
        • 9.3.1.2.4. By Method
        • 9.3.1.2.5. By Cancer Type
        • 9.3.1.2.6. By Application
        • 9.3.1.2.7. By End User
    • 9.3.2. Argentina Multicancer Screening Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value & Volume
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Sample
        • 9.3.2.2.4. By Method
        • 9.3.2.2.5. By Cancer Type
        • 9.3.2.2.6. By Application
        • 9.3.2.2.7. By End User
    • 9.3.3. Colombia Multicancer Screening Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value & Volume
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Sample
        • 9.3.3.2.4. By Method
        • 9.3.3.2.5. By Cancer Type
        • 9.3.3.2.6. By Application
        • 9.3.3.2.7. By End User

10. Middle East and Africa Multicancer Screening Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By Technology
    • 10.2.3. By Sample
    • 10.2.4. By Method
    • 10.2.5. By Cancer Type
    • 10.2.6. By Application
    • 10.2.7. By End User
    • 10.2.8. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Multicancer Screening Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value & Volume
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Sample
        • 10.3.1.2.4. By Method
        • 10.3.1.2.5. By Cancer Type
        • 10.3.1.2.6. By Application
        • 10.3.1.2.7. By End User
    • 10.3.2. Saudi Arabia Multicancer Screening Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value & Volume
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Sample
        • 10.3.2.2.4. By Method
        • 10.3.2.2.5. By Cancer Type
        • 10.3.2.2.6. By Application
        • 10.3.2.2.7. By End User
    • 10.3.3. UAE Multicancer Screening Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value & Volume
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Sample
        • 10.3.3.2.4. By Method
        • 10.3.3.2.5. By Cancer Type
        • 10.3.3.2.6. By Application
        • 10.3.3.2.7. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Agilent Technologies, Inc.
    • 15.6.2. Atara Biotherapeutics, Inc.
    • 15.6.3. Burning Rock Biotech Limited
    • 15.6.4. Exact Sciences Corp.
    • 15.6.5. F. Hoffmann-La Roche Ltd.
    • 15.6.6. Fulgent Genetics, Inc.
    • 15.6.7. Genecast Biotechnology Co., Ltd.
    • 15.6.8. Guardant Health, Inc.
    • 15.6.9. Illumina, Inc. (GRAIL, LLC.)
    • 15.6.10. Konica Minolta, Inc. (Ambry Genetics.)

16. Strategic Recommendations

17. About Us & Disclaimer